445 related articles for article (PubMed ID: 9610872)
1. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
Richard MA; Grob JJ; Zarrour H; Bassères N; Bizzari JP; Gérard B; Bonerandi JJ
Melanoma Res; 1998 Apr; 8(2):170-4. PubMed ID: 9610872
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma.
Semb KA; Aamdal S; Bohmann T; Lucas C; Gerard B
Melanoma Res; 1998 Dec; 8(6):565-72. PubMed ID: 9918419
[TBL] [Abstract][Full Text] [Related]
3. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Tan EH; Ang PT
Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
[TBL] [Abstract][Full Text] [Related]
5. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.
Chiarion Sileni V; Nortilli R; Aversa SM; Paccagnella A; Medici M; Corti L; Favaretto AG; Cetto GL; Monfardini S
Melanoma Res; 2001 Apr; 11(2):189-96. PubMed ID: 11333130
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
[TBL] [Abstract][Full Text] [Related]
8. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
[TBL] [Abstract][Full Text] [Related]
9. Fotemustine plus dacarbazine for malignant melanoma.
Avril MF; Bonneterre J; Cupissol D; Grob JJ; Kalis B; Fumoleau P; Kerbrat P; Israel L; Fargeot P; Lambert D
Eur J Cancer; 1992; 28A(11):1807-11. PubMed ID: 1389514
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.
Chang J; Atkinson H; A'Hern R; Lorentzos A; Gore ME
Eur J Cancer; 1994; 30A(14):2093-5. PubMed ID: 7857710
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group.
Avril MF; Bonneterre J; Delaunay M; Grosshans E; Fumoleua P; Israel L; Bugat R; Namer M; Cupissol D; Kerbrat P
Cancer Chemother Pharmacol; 1990; 27(2):81-4. PubMed ID: 2249337
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
Margolin KA; Liu PY; Flaherty LE; Sosman JA; Walker MJ; Smith JW; Fletcher WS; Weiss GR; Unger JM; Sondak VK
J Clin Oncol; 1998 Feb; 16(2):664-9. PubMed ID: 9469356
[TBL] [Abstract][Full Text] [Related]
13. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
[TBL] [Abstract][Full Text] [Related]
14. Fotemustine and DTIC combination in patients with disseminated malignant melanoma.
Merimsky O; Inbar M; Chaitchik S
Am J Clin Oncol; 1992 Feb; 15(1):84-6. PubMed ID: 1550085
[TBL] [Abstract][Full Text] [Related]
15. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
16. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
Rixe O; Borel C; Paraiso D; Benhammouda A; Petit T; Antoine E; Bizzari JP; Auclerc G; Soubrane C; Weil M
Melanoma Res; 1995 Dec; 5(6):419-24. PubMed ID: 8589616
[TBL] [Abstract][Full Text] [Related]
17. Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine.
Seeber A; Binder M; Steiner A; Wolff K; Pehamberger H
Eur J Cancer; 1998 Dec; 34(13):2129-31. PubMed ID: 10070323
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation.
Mc Clay EF; Mc Clay ME; Albright KD; Jones JA; Christen RD; Alcaraz J; Howell SB
Cancer; 1993 Sep; 72(6):1914-8. PubMed ID: 8364868
[TBL] [Abstract][Full Text] [Related]
19. High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.
Buzaid AC; Murren JR; Durivage HJ
Cancer; 1991 Sep; 68(6):1238-41. PubMed ID: 1873775
[TBL] [Abstract][Full Text] [Related]
20. Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation.
Ulrich J; Gademann G; Gollnick H
J Neurooncol; 1999 Jun; 43(2):173-8. PubMed ID: 10533730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
